https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43081 Tue 13 Sep 2022 12:19:26 AEST ]]> Translating research into practice: Outcomes from the Healthy Living after Cancer partnership project https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54244 Tue 13 Feb 2024 13:18:32 AEDT ]]> Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46000 C and ABCB1_c.3435C > T were included in the final model, whereby CLSN38 reduced from 76.8 to 55.1%. Conclusion: The identified UGT1A3_c.31 T > C and ABCB1_c.3435C > T variants, from wild type to homozygous, were included in the final model for SN38 clearance.]]> Tue 08 Nov 2022 16:32:22 AEDT ]]> Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12335 Sat 24 Mar 2018 08:15:52 AEDT ]]> From inside the bubble: migrants' perceptions of communication with the cancer team https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12251 Sat 24 Mar 2018 08:08:09 AEDT ]]> A bridge between cultures: interpreters' perspectives of consultations with migrant oncology patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23157 Sat 24 Mar 2018 07:10:35 AEDT ]]>